Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients

ABSTRACTBreast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse clinical classifications. In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herceptin, have shown well-defined therapeutic effe...

Full description

Bibliographic Details
Main Authors: Yu Song, Qiao-Chen Geng, Wen-Jing An, Fu-Cheng Zhang, Ran Jiang, Rui-Sheng Zhao, Zhi-Jian Deng, Heng Li
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Molecular & Cellular Oncology
Subjects:
Herceptin
breast cancer
macrophages
chemotaxis
Online Access:https://www.tandfonline.com/doi/10.1080/23723556.2024.2309715

Similar Items

Similar Items